[HTML] sciencedirect.com

[HTML][HTML] Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory …

EB Garon, M Reck, K Nishio, JV Heymach, M Nishio… - ESMO open, 2023 - Elsevier
Background Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) over placebo+ ERL (PBO+ ERL) in the phase III RELAY study of patients …
被引用次数：7 相关文章

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis …

EB Garon, M Reck, K Nishio, JV Heymach, M Nishio… - ESMO Open, 2023 - europepmc.org
Background Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) over placebo+ ERL (PBO+ ERL) in the phase III RELAY study of patients …

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis …

EB Garon, M Reck, K Nishio, JV Heymach, M Nishio… - ESMO OPEN, 2023 - iris.unito.it
Background: Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) over placebo+ ERL (PBO+ ERL) in the phase III RELAY study of patients …

[引用][C] Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory …

EB Garon, M Reck, K Nishio, JV Heymach… - ESMO …, 2023 - produccioncientifica.ucm.es
Background: Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) over placebo+ ERL (PBO+ ERL) in the phase III RELAY study of patients …

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis …

RELAY Study Investigators - ESMO Open, 2023 - mdanderson.elsevierpure.com
Background: Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) over placebo+ ERL (PBO+ ERL) in the phase III RELAY study of patients …
[HTML] nih.gov

[HTML][HTML] Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory …

EB Garon, M Reck, K Nishio, JV Heymach, M Nishio… - ESMO Open, 2023 - ncbi.nlm.nih.gov
Background Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) over placebo+ ERL (PBO+ ERL) in the phase III RELAY study of patients …

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis …

EB Garon, M Reck, K Nishio, JV Heymach… - ESMO … - pubmed.ncbi.nlm.nih.gov
Background Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) over placebo+ ERL (PBO+ ERL) in the phase III RELAY study of patients …
[HTML] esmoopen.com

[HTML][HTML] Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory …

EB Garon, M Reck, K Nishio, JV Heymach, M Nishio… - ESMO Open, 2023 - esmoopen.com
Background Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) over placebo+ ERL (PBO+ ERL) in the phase III RELAY study of patients …

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis …

EB Garon, M Reck, K Nishio, JV Heymach, M Nishio… - ESMO Open, 2023 - europepmc.org
Background Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) over placebo+ ERL (PBO+ ERL) in the phase III RELAY study of patients …
[PDF] unito.it

[PDF][PDF] Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory …

EB Garon, M Reck, K Nishio, JV Heymach, M Nishio… - iris.unito.it
Background: Ramucirumab plus erlotinib (RAM þ ERL) demonstrated superior progression-
free survival (PFS) over placebo þ ERL (PBO þ ERL) in the phase III RELAY study of patients …